Moderna's cancer vaccine actually hit the finish line

Moderna and Merck announced that their mRNA cancer vaccine passed its Phase 3 trial for melanoma — the disease that kills the most people among skin cancers. This isn't a lab curiosity; it's the first time an mRNA cancer vaccine has cleared the final regulatory hurdle. The drug works by teaching the immune system to recognize tumor-specific mutations, which is a fundamentally different approach from chemo or checkpoint inhibitors.

The news is big for a reason. For the last few years, cancer vaccines have been a lot of hype and almost no results. The mRNA platform had been betting on infectious disease — COVID, flu, RSV — and investors were starting to wonder if cancer was the wrong bet. This trial flips that narrative. It doesn't cure melanoma outright, but it gives the immune system a target it can actually hit. That matters for anyone in the familia who's had a loved one fight melanoma, because this is one of the cancers that spreads fast and hits hard.

The company hasn't filed for FDA approval yet, so there's still a regulatory path to walk and manufacturing to scale. But the biology worked. This is the kind of story the biotech press treats like a headline-grabber, and for once it actually deserves the attention.

Why this matters for us: when a cancer vaccine works, the people who benefit most are the ones who can't afford the $150,000 a year treatments that come next.